A rapid decrease in parasitaemia remains the major goal for new antimalarial drugs and thus, in vivo models must provide precise results concerning parasitaemia modulation. Hydroxyethylamine comprise an important group of alkanolamine compounds that exhibit pharmacological properties as proteases inhibitors that has already been proposed as a new class of antimalarial drugs. Herein, it was tested the antimalarial property of new nine different hydroxyethylamine derivatives using the green fluorescent protein (GFP)-expressing Plasmodium berghei strain. By comparing flow cytometry and microscopic analysis to evaluate parasitaemia recrudescence, it was observed that flow cytometry was a more sensitive methodology. The nine hydroxyethylamine derivatives were obtained by inserting one of the following radical in the para position: H, 4Cl, 4-Br, 4-F, 4-CH3, 4-OCH3, 4-NO2, 4-NH2 and 3-Br. The antimalarial test showed that the compound that received the methyl group (4-CH3) inhibited 70% of parasite growth. Our results suggest that GFP-transfected P. berghei is a useful tool to study the recrudescence of novel antimalarial drugs through parasitaemia examination by flow cytometry. Furthermore, it was demonstrated that the insertion of a methyl group at the para position of the sulfonamide ring appears to be critical for the antimalarial activity of this class of compounds.
A rapid decrease in parasitaemia remains the major goal for new antimalarial drugs and thus, in vivo models must provide precise results concerning parasitaemia modulation. Hydroxyethylamine comprise an important group of alkanolamine compounds that exhibit pharmacological properties as proteases inhibitors that has already been proposed as a new class of antimalarial drugs. Herein, it was tested the antimalarial property of new nine different hydroxyethylamine derivatives using the green fluorescent protein (GFP)-expressing Plasmodium berghei strain. By comparing flow cytometry and microscopic analysis to evaluate parasitaemia recrudescence, it was observed that flow cytometry was a more sensitive methodology. The nine hydroxyethylamine derivatives were obtained by inserting one of the following radical in the para position: H, 4Cl, 4-Br, 4-F, 4-CH3, 4-OCH3, 4-NO2, 4-NH2 and 3-Br. The antimalarial test showed that the compound that received the methyl group (4-CH3) inhibited 70% of parasite growth. Our results suggest that GFP-transfected P. berghei is a useful tool to study the recrudescence of novel antimalarial drugs through parasitaemia examination by flow cytometry. Furthermore, it was demonstrated that the insertion of a methyl group at the para position of the sulfonamide ring appears to be critical for the antimalarial activity of this class of compounds.
Malaria is the most relevant parasitic disease and, despite the many efforts made to
eradicate malaria, the disease still accounts for 0.5 million deaths per year globally
(WHO 2015). In Brazil, despite the number of
cases has been decreasing, it still accounts for 177,767 cases in 2013 (de Pina-Costa et al. 2014, WHO 2015). The current antimalarial treatment recommended by World Health
Organization (WHO) is artemisinin-based combination therapy because of artemisinin’s
efficacy and ability to lower the rate at which resistance emerges (WHO 2010). However, several cases of resistance to artemisinin
derivatives have been observed, first at the Cambodia-Thailand border (Dondorp et al. 2010) and now spread across Southeast
Asia (Ashley et al. 2014). Such a scenario compels
the discovery of novel antimalarial drugs. Several approaches have been used in
antimalarial drug discovery, including the use of drugs that prevent transmission or new
infection, stop relapse or can be used in cases of uncomplicated and severe malaria (Aguiar et al. 2012a, Anthony et al. 2012). However, a rapid decrease in parasitaemia remains the
major goal for new drugs (Burrows et al. 2013).The biological activities of hydroxyethylamine core have been extensively studied.
Hydroxyethylamines have been described as human immunodeficiency virus (HIV) protease
inhibitors (Ghosh et al. 2014) and, over the last
several years, this class have been studied for their antimalarial activity (de Souza et al. 2012). The antimalarial mechanism of action
of hydroxyethylamines comprises the selective inhibition of plasmodium proteases such as
falcipain and plasmepsin without interfering with human proteases (Muthas et al. 2005, Rathi et al.
2013). Indeed, the study of hydroxyethylamine derivatives as a new class of
antimalarial drugs could represent a safe antimalarial drug. Recently, it was demonstrated
that the insertion of a ciclohexyl group in hydroxyethylamine core synthesised from
alkylamines increase the antimalarial of such molecule (de Souza et al. 2012).Herein, it was tested newly synthesised nine different hydroxyethylamine derived from
ring-opening of the (2S,3S)-Boc-phenylalanine epoxide with benzylamine in refluxing
isopropanol, according its antimalarial activity using the mouse in vivo model of infection
with green fluorescent protein-expressing Plasmodium berghei (PbGFP).
MATERIALS AND METHODS
Ethics statement - This work was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Committee on Ethical Use
of Laboratory Animals of the Oswaldo Cruz Foundation (Fiocruz) (Rio de Janeiro, Brazil)
(permit LW52/12).Mice and the model of infection - C57BL/6 mice (4-5 weeks old) were
provided by the Fiocruz breeding unit and caged with free access to food and fresh water
in a room at the Farmanguinhos experimental facility, with a temperature ranging from
22-24ºC and a 12 h light/dark cycle, until use.For the nontransfected and PbGFP ANKA infection [GFPcon 259cl2 was kindly provided by Dr
L Carvalho (Fiocruz) and is a donations from the Malaria Research and Reference Reagent
Resource Center - MR4, deposited by CJ Janse and AP Waters (MRA-865)], the mice were
intraperitoneally (i.p.) inoculated with 5 x 106
P. berghei-parasitised red blood cells withdrawn from a previously
infected mouse. Artesunate, chloroquine or primaquine was orally administered to mice on
the third day of infection (100 mg/kg, diluted in 10% ethanol and 90% propylene glycol;
Farmanguinhos). For the evaluation of survival rate, lethality was registered every day
until day 14 post-infection. Mice were euthanised by an i.p. injection with a mixture of
ketamine (100 mg/kg) and xylazine (10 mg/kg) prior to pentobarbital (150 mg/kg).Parasitaemia evaluation - At the indicated time points after infection,
a thin blood smear was performed for parasitaemia determination by Diff-Quick staining.
The determination of parasitaemia by microscopy was performed by counting five fields of
approximately 200 erythrocytes per field. To evaluate parasitaemia by flow cytometry, 4
µL of blood was resuspended in 500 µL of phosphate buffered saline/0.1% azide and the
cell suspension was immediately submitted to flow cytometry (FACSCalibur, BD
Biosciences), as described (Franke-Fayard et al.
2004). Forward scatter and side scatter were set to gate the total
erythrocytes and the percentage of PbGFP-infected erythrocytes was determined by
fluorescence intensity. At least 10,000 events were acquired in the gate. The data
analyses were performed using CellQuest software (BD Immunocytometry Systems, USA).Antimalarial activity of hydroxyethylamine derivatives - The target
compounds 5a-i were obtained as previously described (Facchinetti et al. 2014, Moreth et al.
2014). To evaluate the in vivo antimalarial efficacy of hydroxyethylamine
derivatives, the PbGFP four-day suppressive test was used (Fidock et al. 2004). Two hours after infection with PbGFP, mice were
randomly assigned to 11 groups: nontreated (vehicle, 200 μL i.p.), artesunate treated
[10 mg/kg/day diluted in 5% dimethyl sulfoxide (DMSO)] and a group for each
hydroxyethylamine derivatives (5a-i; 10 mg/kg/day diluted in 5% DMSO). Mice were treated
daily up to day 4 after infection when parasitaemia determination was performed by flow
cytometry. The results are expressed as drug activity as described previously (Fidock et al. 2004). The difference between the mean
value of the control group (taken as 100%) and that of the experimental groups was
calculated and expressed as percent reduction (= activity) using the following equation:
activity = 100 - [(mean parasitaemia treated/mean parasitaemia control) x 100].Statistical analysis - A log-rank (Mantel-Cox) test was used to compare
the percentages of survival and the significance level was set at p < 0.05. The
correlation coefficient and Bland-Altman limit were calculated. Additional statistical
significance was assessed using ANOVA followed by the Newman-Keuls t
test. The results are expressed as the mean ± standard error of the means and the
significance level in all cases was set at p < 0.05.
RESULTS
Comparison of recrudescence test using Pb and PbGFP-infected mice - In
view of the importance to observe the rapid decrease of parasitaemia after antimalarial
treatment, it was first compared two methodologies used to the test of new antimalarial
drugs (Aguiar et al. 2012b, de Souza et al. 2012).
It was observed that Pb and PbGFP-infected mice exhibited similar survival curves (p =
1.00) (Fig. 1A). In addition, the parasitaemia in
the Pb and PbGFP groups, as counted by microscopy, was not statistically different and
increased up to day 6 post-infection (Fig. 1B).
PbGFP-infected erythrocytes were further counted by flow cytometry and it was observed
increased levels of parasitaemia up to day 6 post-infection (Fig. 1C). A positive correlation was observed between the
parasitaemia counted by microscopy from Pb and PbGFP-infected mice (Fig. 2A). In addition, the evaluation of parasitaemia from
PbGFP-infected mice analysed by microscopy or by flow cytometry revealed a significant
positive linear correlation (p = 0.006) (Fig. 2B).
To confirm that two different methodologies would infer the same result, it was
performed a Bland-Altman analysis that also indicated that the evaluation of
parasitaemia by cytometry and by microscopy are equivalent (bias = 0.1%; 95% limit of
agreement = 4.2%) (Fig. 2C).
Fig. 1A
: survival rates for C57BL/6 mice infected with Plasmodium
berghei (Pb) (solid line) or green fluorescent protein-expressing
Pb (PbGFP) (dashed line). The log-rank test revealed no differences in the
survival curves when the Pb-infected (n = 10) and PbGFP-infected C57BL/6 mice
(n = 10) were compared. Evolution of parasitaemia in Pb (black symbols) or
PbGFP-infected (white symbols) mice measured by microscopy (B) or cytometry
(C). The results are expressed as the mean ± standard deviation from at least
six animals per group in two different experiments. Gating strategy used to
isolate total red blood cells (RBCs) based on forward scatter (FSC) and side
scatter (SSC), and representative dot-plots demonstrate the increase in
fluorescence, as indicated by an increase in GFP expression in the RBCs is
shown in C.
Fig. 2
: correlation analyses of parasitaemia estimated by microscopy and
cytometry. A: correlation between parasitaemia in mice infected with
Plasmodium berghei (Pb) or green fluorescent
protein-expressing Pb (PbGFP) evaluated by microscopy; B: correlation between
parasitaemia in PbGFP-infected mice evaluated by microscopy and cytometry; C:
Bland-Altman plot representing the bias (0.1%) and 95% limit of agreement
(4.2%) for the parasitaemia evaluation.
Concerning recrudescence studies, up to 48 h after treatment with chloroquine, no
infected erythrocytes were found in the blood smears obtained from treated mice (Fig. 3A-C, respectively). However, using flow
cytometry, an increase in the parasitaemia of treated mice was observed, especially in
mice treated with primaquine or chloroquine. At 72 h and 96 h after treatment, infected
erythrocytes were observed in the blood smears at the same extent observed by flow
cytometry.
Fig. 3
: evaluation of recrudescence after treatment with antimalarial drugs. Mice
were infected with green fluorescent protein-expressing Plasmodium
berghei (PbGFP) and treated with artesunate (A), chloroquine (B) or
primaquine (C) at day 3 post-infection and parasitaemia was evaluated up to 96
h after treatment. Parasitaemia was evaluated by microscopy (black bars) and
cytometry (hatched bars). The results are expressed as the mean ± standard
deviaton from at least six animals per group in two different experiments.
Statistically significant differences compared to the group evaluated by
microscopy (p < 0.05) are indicated by an asterisk.
Antimalarial activity of hydroxyethylamine derivatives - Because PbGFP
is an effective model to study antimalarial drugs, PbGFP-infected mice were treated with
nine hydroxyethylamine derivatives
((2S,3R)-2-(amino)-[4-(N-benzylarenesulfonamido)-3-hydroxy-1-phenylbutane). The
preparation of the target compounds 5a-i (Fig. 4)
has been previously described (Facchinetti et al.
2014, Moreth et al. 2014).
Of the nine tested compounds, 5a and 5e showed antimalarial activity. Compound 5e was
able to reduce 70% of the parasitaemia and was the most active substance of this series
(Fig. 5).
Fig. 5
: antimalarial activity of the hydroxyethylamine derivatives. The mice were
treated daily with artesunate (ART) or derivatives (10 mg/kg/day;
intraperitoneally). Drug activity was evaluated at day 4 after infection and is
expressed as (A) parasitaemia levels or as (B) activity, according the
following equation: activity = 100 - [(mean parasitaemia treated/mean
parasitaemia control) x 100]. It was used at least six animals per group in two
different experiments.
DISCUSSION
Herein, it was proposed the study of newly synthesised hydroxyethylamine derivatives as
antimalarial compounds using PbGFP. Furthermore, it was observed that parasitaemia
evaluation by flow cytometry reveal low parasitaemia levels, which is not observed by
microscopic analysis.As described before, according the Medicine for Malaria Venture, the “ideal” candidate
profile of an antimalarial drug is whom account for fast parasite clearance over 48 h
after treatment (Burrows et al. 2013). In such
way, it is important to use techniques for parasite evaluation that lead to accurate
results. The construction of PbGFP was performed by Franke-Fayard et al. (2004) and has been used in a wide range of studies
(Sultan et al. 1999, Sanchez et al. 2004, Tewari et al.
2010, de Souza et al. 2012), including
the screening of novel antimalarial drugs (de Souza et
al. 2012, Lam et al. 2013, Wang et al. 2014). It is interesting to note the
presence of infected erythrocytes up to 48 h after treatment with chloroquine by flow
cytometry that was not detected by microscopic analysis. Flow cytometry allows faster
and accurate parasitaemia examination because this technique can identify small amounts
of parasites in the blood (Malleret et al. 2011).
Although flow cytometry is a costly and complex technology to examine parasitaemia for
routine diagnosis purposes, the required instrumentation and materials are widely
available in research and development institutions for research purpose (Shapiro et al. 2013). Parasitaemia evaluation by
microscopic examination, despite widely used as main test for diagnosis purposes (WHO 2015), is labour and time-consuming, as well as
dependent on microscopist training and ability (Payne
1988). Limitations for PbGFP usage as a tool for the discovery of
pyrimethamine-based drugs should be addressed, since the construction of PbGFP required
the insertion of pyrimethamine-resistant gene at the same vector where GFP gene is
insert aiming to select the successfully transfected parasites.Hydroxyethylamine derivative has been used in different biological approaches, as HIV-1
protease inhibitor (Ghosh et al. 2014) and
inhibitor of β-secretase 1, an enzyme associated with neurodegeneration (Nordeman et al. 2014). As well, the
hydroxyethylamine-based compounds has been tested as antimalarial drugs since this
compounds are able to inhibit the activity of plasmepsin (Muthas et al. 2005) and falcipain (Rathi et al. 2013), main enzymes involved in parasite development (Blackman 2008). It was previously showed that
hydroxyethylamine derivatives (ciclohexyl group inserted in hydroxyethylamine core)
synthesised from alkylamines presented antimalarial activity (de Souza et al. 2012). Herein, it was tested the in vivo activity of new
nine different ((2S,3R)-2-(amino)-[4-(N-benzylarenesulfonamido)-3-hydroxy-1-phenylbutane
derivatives and observed that the insertion of a methyl group at the
para position of the sulfonamide ring appears to be critical for the
antimalarial activity of this class of compounds (Fig.
6). Interestingly, hydroxyethylamine exhibits no toxic effect on erythrocytes
and does not inhibit human proteases (Muthas et al.
2005), suggesting that hydroxyethylamine derivatives would be safe and
effective novel antimalarial drugs. In fact, its biological activity may be attributed
to a secondary alcohol structural element, which mimics the tetrahedral intermediate
during metabolite cleavage by proteases (Cunico et al.
2009). In addition, Jaudzems et al.
(2014) showed that the insertion of two methyl group in
hydroxyethylamine-based compounds increased compound activity on Plasmodium
faciparum enzymes when compared to nonmethylated compound.
Fig. 6
: structure-activity relationship for the studied hydroxyethylamine 5a-i
series.
Together, our results suggest that PbGFP is a useful tool to study the recrudescence of
novel antimalarial drugs through parasitaemia examination by flow cytometry.
Furthermore, it was demonstrated that the insertion of a methyl group at the
para position of the sulfonamide ring appears to be critical for the
antimalarial activity of this class of compounds.
Authors: Mariana Conceição de Souza; Triciana Gonçalves-Silva; Marcele Moreth; Claudia R B Gomes; Carlos Roland Kaiser; Maria das Graças Muller de Oliveira Henriques; Marcus V N de Souza Journal: Med Chem Date: 2012-03 Impact factor: 2.745
Authors: Anna Caroline C Aguiar; Eliana M M da Rocha; Nicolli B de Souza; Tanos C C França; Antoniana U Krettli Journal: Mem Inst Oswaldo Cruz Date: 2012-11 Impact factor: 2.743
Authors: Blandine Franke-Fayard; Holly Trueman; Jai Ramesar; Jacqui Mendoza; Maarten van der Keur; Reinier van der Linden; Robert E Sinden; Andrew P Waters; Chris J Janse Journal: Mol Biochem Parasitol Date: 2004-09 Impact factor: 1.759
Authors: Arun K Ghosh; Gary E Schiltz; Linah N Rusere; Heather L Osswald; D Eric Walters; Masayuki Amano; Hiroaki Mitsuya Journal: Org Biomol Chem Date: 2014-09-21 Impact factor: 3.876
Authors: Jeremy N Burrows; Rob Hooft van Huijsduijnen; Jörg J Möhrle; Claude Oeuvray; Timothy N C Wells Journal: Malar J Date: 2013-06-06 Impact factor: 2.979
Authors: Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells Journal: Malar J Date: 2012-09-07 Impact factor: 2.979
Authors: Mohan Liu; Matthew J Liao; Christopher J Fisher; Rodolfo D Vicetti Miguel; Thomas L Cherpes Journal: J Microbiol Methods Date: 2022-03-04 Impact factor: 2.363
Authors: Yash Gupta; Neha Sharma; Snigdha Singh; Jesus G Romero; Vinoth Rajendran; Reagan M Mogire; Mohammad Kashif; Jordan Beach; Walter Jeske; Bernhards R Ogutu; Stefan M Kanzok; Hoseah M Akala; Jennifer Legac; Philip J Rosenthal; David J Rademacher; Ravi Durvasula; Agam P Singh; Brijesh Rathi; Prakasha Kempaiah Journal: Pharmaceutics Date: 2022-06-28 Impact factor: 6.525